Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Open Access
- 5 July 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 10 (1), 1-8
- https://doi.org/10.1186/s13045-017-0506-z
Abstract
Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunotherapy in 270 clinical studies. However, Chinese clinical trials of these agents remain in the early stages. We summarize the ongoing international and domestic clinical trials using PD-1 and PD-L1 inhibitors to treat lung cancer. This information can help researchers better understand the active and approved clinical trials in China, as well as the ongoing research regarding PD-1 and PD-L1 inhibitors.Keywords
Funding Information
- Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine (2012A061400006)
- Special Fund for Research in the Public Interest from National Health and Family Planning Commission of PRC (201402031)
- Research Fund from Guangzhou Science and Technology Bureau (2014Y2-00050)
This publication has 26 references indexed in Scilit:
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyThe Lancet Oncology, 2016
- Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western ChinaScientific Reports, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Novel targeted agents for the treatment of lung cancer in ChinaCancer, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodiesLung Cancer Management, 2014
- Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of ChinaLung Cancer: Targets and Therapy, 2014
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)Journal of Thoracic Oncology, 2014